Episurf Medical Ab Class B · OMXSTO:EPIS_B
Episurf Medical Ab Class B — Shareholder Meeting (May 2023)
29 slides from Episurf Medical Ab Class B's shareholder meeting presentation, May 2023
Slide 1: Episurf Medical
Episurf Medical Investor Presentation March, 2023 Annual General Meeting 2023 Stockholm, May 2023 episurf.com episurf.com
Slide 2: Episealer Knee – Addressing an unmet clinical need
Episealer® Knee – Addressing an unmet clinical need Today, there is no cure for the osteoarthritic (“OA”) process. Joint cartilage has poor capacity to regenerate • Arthritis, of which osteoarthritis is the most common type, is the most frequent cause of disability in the United States − Knee OA is
Slide 3: Episealer Knee – Addressing an unmet clinical need
Episealer® Knee – Addressing an unmet clinical need Today, there is no cure for the osteoarthritic (“OA”) process. Joint cartilage has poor capacity to regenerate • Arthritis, of which osteoarthritis is the most common type, is Illustration/Stages of cartilage break-down/degeneration the most freque
Slide 4: Illustration of treatment gap
Illustration of treatment gap In combination with a strong focus on the generation and publication of clinical evidence in the last years, Episurf has systematically worked with an ambitious regulatory agenda, to seriously address the treatment gap globally Population in Episurf’s current target mar
Slide 5: Illustration of treatment gap
Illustration of treatment gap Episealer® patients are found in every corner of the treatment gap, and sometimes people zoom in on the absolute center of the gap – missing out on an enormous market potential, including a strategic positioning that no other company has 55-year-old – treated with tripl
Slide 6: Illustration of treatment gap
Illustration of treatment gap Episealer® patients are found in every corner of the treatment gap, and sometimes people zoom in on the absolute center of the gap – missing out on an enormous market potential, including a strategic positioning that no other company has 55-year-old – treated with tripl
Slide 7: Only one firm will truly shape the offering of tomorrow
Only one firm will truly shape the offering of tomorrow Osteoarthritis (OA) is an irreversible degenerative disease that once symptomatic, will only worsen over time The future implant offering – Serving any patient at any stage of the OA-process Early intervention implants Partial Knee Systems Tota
Slide 8: Total Knees in younger patients do significantly worse
Total Knees in younger patients do significantly worse Data from the 19th Annual UK National Joint Registry1 • 1.44 million knee replacements studied • From the date of surgery, results get worse the younger patients get • Furthermore, nearly 20% of patients are dissatisfied with their knee replacem
Slide 9: The Episealer technology platform
The Episealer® technology platform Episealer® technology Implant technology Software Knee Lower extremities Imaging Episealer® Knee Episealer® Episealer® Talus Talus Osteotomy Episealer® MTP- Image Damage marking Epioscopy® Patellofemoral Guide system segmentation report System Implant and Implant a
Slide 10: Intellectual property
Intellectual property Granted / pending patents Continuous and robust work since inception • >200 patents and patent applications • ~80 % approved • >35 patent families • ~20 registered & pending design registrations • ~30 registered & pending trademark registrations Patent Applications Patent Regis
Slide 11: Intellectual property
Intellectual property Key word search results – Episurf IP portfolio Illustration / examples – Episurf IP portfolio Method of Surgical kit with implant and Semiconductors 2% designing a patient-specific guide tool with Implant for cartilage repair surgical kit based a guide tower fitting the with a
Slide 12: Summary of our Targeted Market Segments
Summary of our Targeted Market Segments Knee (USDm) Lower extremities (USDm) +USD 1bn +USD 1bn TBU +250 400 400 1.120 600 400 120 Episealer Knee Episealer Patellofemoral System TAM: Knee Episealer Talus Episealer MTP System TAM: F&A US OUS US OUS Global Global US OUS Global 600 400 +250 TBU +1bn 120
Slide 13: Regulatory clearance
Regulatory clearance North America EMEA APAC • Following a strategic decision in 2017 to expand the geographical focus, Episurf has established a global presence • During LTM, Episealer surgeries have taken place in 20 countries • Germany still represents the majority of revenue generation Market ap
Slide 14: Market Overview and Strategic Positioning
Market Overview and Strategic Positioning Clinical & Competitive Episealer® Knee Indication landscape Regulatory Market barriers Category Focal lesion Lower Higher creation Category Focal lesion Lower Higher creation OA Higher Lower Established (Osteoarthritis) OA Higher Lower Established (Osteoarth
Slide 15: Market Overview and Strategic Positioning
Market Overview and Strategic Positioning Clinical & Competitive Episealer® Talus Indication landscape Regulatory Market barriers Category Focal lesion Lower Higher creation Category Focal lesion Lower Higher creation OA Higher Lower Established (Osteoarthritis) OA Higher Lower Established (Osteoart
Slide 16: Market Overview and Strategic Positioning
Market Overview and Strategic Positioning Clinical & Competitive Episealer® Patellofemoral System Indication landscape Regulatory Market barriers Category Focal lesion Lower Higher creation Category Focal lesion Lower Higher creation OA Higher Lower Established (Osteoarthritis) OA Higher Lower Estab
Slide 17: Market Overview and Strategic Positioning
Market Overview and Strategic Positioning Clinical & Competitive Episealer® MTP-system Indication landscape Regulatory Market barriers Category Focal lesion Lower Higher creation Category Focal lesion Lower Higher creation OA Higher Lower Established (Osteoarthritis) OA Higher Lower Established (Ost
Slide 18: Problems Plaguing Existing Patellofemoral Devices
Problems Plaguing Existing Patellofemoral Devices Progression (or fear) of OA into the tibiofemoral joint ✓ Episurf Solution – playing a supportive role in surgeon’s patient selection process via Damage Marking Reports detailing the condition of the entire knee “Overstuffing” of the joint ✓ Episurf
Slide 19: Competitive Matrix
Competitive Matrix ONLY Episurf assists in patient selection by profiling the entire knee’s cartilage condition Big/Personalized Small/Personalized No implant offering Only partially personalized Just right Big/Off-the-Shelf Small/Off-the-Shelf Too Bulky Too imprecise 19
Slide 20: 1st MTP – A market with a history of fast adoption
1st MTP – A market with a history of fast adoption 2018 Normal ROM Cartiva acquired by > 90° dorsiflexion Wright Medical (USD 435m) 2018 Early 2021 Mid-2023 Cartiva sales of Episurf re-start of Expected 510(k) Hallux Limitus USD 35m project submission < 45° dorsiflexion ⚫ ✓ ✓ ✓ ✓ Hallux Rigidus
Slide 21: MTP Joint – Competitive Landscape
MTP Joint – Competitive Landscape Medical Management Currently Available Implant Options Fusion NSAIDs Lack precision • Most common Footwear modifications Limit motion • “Last” surgical option before Ice Bulky designs amputation Not corrective or Burn bridges for future surgeries N
Slide 22: Commercial strategy update
Commercial strategy update Recently, Episurf has initiated a complete oversight of the commercial activities under the leadership of Steve Caswell (OUS) and Patrick Jamnik (US), focusing on ensuring the best team of direct reps and distributors. In addition, we are updating our branding and messagin
Slide 23: Summary of Target Market(s)
Summary of Target Market(s) Est. no. Est. market Strategic focus Product of surgeons opportunity ($m) < 5 yrs > 5 yrs Episealer® Knee 600 Clin./Regulatory Commercial US 11 000 Episealer® PFJ +250 Commercial Commercial Knee Episealer® Knee 400 Commercial Commercial OUS 11 560 Episealer® PFJ TBD Clin.
Slide 24: Milestones
Milestones Market 2023 2024 2025 2026 Targets opportunity + RoW Commercialization ~USD 0.4bn Long-term: 30% Episealer® 3-yrs post PMA Knee approval: 15% Patient recruitment Patient follow-ups PMA ~USD 0.6bn Episealer® Talus + RoW Commercialization and data generation ~USD 60m TBD Episealer® Patellof
Slide 25: Shareholders
Shareholders Shares (000s) % holding Shareholders, March 31, 2023 A B votes capital 1 Health Runner AB (Ilija Batljan) -- 34,771 13.0% 13.0% 2 Rhenman Partners -- 12,668 4.7% 4.7% 3 Fjärde AP-Fonden -- 12,537 4.7% 4.7% 4 Sebastian Jahreskog -- 11,893 4.4% 4.5% 5 Tredje AP-Fonden -- 9,980 3.7% 3.7% 6
Slide 26: Management Team
Management Team Name Pål Ryfors Veronica Wallin Katarina Flodström Patrick Jamnik Fredrik Zetterberg Stephen Caswell Michael Näsström Head of Quality & Role CEO CFO Chief Operating Officer President Episurf Medical Inc. Marketing Director Head of Sales, OUS Regulatory Affairs Background Joined Episu
Slide 27: Board of Directors
Board of Directors Ulf Grunander Leif Ryd Proposed Chairman Founder and Board Member Mr Ulf Grunander previously Prof. Ryd is an orthopedic served 23 years as CFO for surgeon with a long career in Getinge Group. Mr. Grunander clinical research, focusing on currently sits on the boards of Arjo AB (pu
Slide 28: Summary
Summary • Category creation and established markets • RnD efforts and customer input have led us to expand into additional joints • Several processes targeting the US market • Focus on all commercial channels – Direct markets – Indirect markets • Aligned with major orthopaedic trends 28
Slide 29: Episurf Medical
Episurf Medical Investor Presentation March, 2023 Annual General Meeting 2023 Stockholm, May 2023 episurf.com episurf.com